Navigation Links
Rigel Announces Initiation of Clinical Trials in Two Immunology Programs
Date:1/5/2012

equate response with methotrexate alone. AZ expects to file a New Drug Application for fostamatinib in the U.S. and a European equivalent in 2013. The Companies will provide more specific timing as that milestone approaches.

Webcast Details

To access the live audio webcast of the company presentation at the J.P. Morgan Conference or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis, R343, an inhaled SYK inhibitor that has completed Phase 1 clinical trials for asthma, R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders, and R333, a topical JAK/SYK inhibitor for the treatment of discoid lupus.

This press release contains "forward-looking" statements, including, without limitation, statements related to Rigel's future product candidate pipeline and strategy, the potential uses and efficacy of Rigel's product candidates, the timing and design of its future clinical trials and potential milestones and regulatory filings associated with Rigel's product candidates.
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel to Present at Oppenheimer Annual Healthcare Conference
2. Rigel Announces Third Quarter 2011 Financial Results
3. Rigel to Present at Two Upcoming Investor Conferences
4. Rigel to Present at Wells Fargo Securities Healthcare Conference
5. Rigel to Present at Jefferies Global Healthcare Conference
6. Rigel Announces Pricing of Public Offering of Common Stock
7. Rigel Announces Proposed Public Offering of Common Stock
8. Rigel to Present at Bank of America Merrill Lynch Health Care Conference
9. Rigel Announces First Quarter Financial Results
10. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
11. Rigel to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Sept. 1, 2015  Abbott (NYSE: ABT ) announced ... multi-center, randomized trial comparing the safety and effectiveness of ... ® , Abbott,s market-leading, permanent drug eluting stent. The ... Japan and enrolled 400 people with coronary ... The results will be featured at a late-breaking session ...
(Date:9/1/2015)... Quebec , Sept. 1, 2015  Valeant ... TSX: VRX) today announced that its affiliate has ... which Valeant was granted an exclusive license to ... is an IL-17 receptor monoclonal antibody in development ... arthritis. Under the agreement, Valeant will hold the ...
(Date:8/31/2015)... TWINSBURG, Ohio , Aug. 31, 2015 /PRNewswire/ ... and applications, has acquired MACTek Corporation, a leading ... part of Pepperl+Fuchs, strategy to further extend its ... the WirelessHART market.    "We are ... to our existing portfolio," said Jim Bolin ...
Breaking Medicine Technology:Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4Valeant And AstraZeneca To Partner On Brodalumab 2Valeant And AstraZeneca To Partner On Brodalumab 3Valeant And AstraZeneca To Partner On Brodalumab 4
(Date:9/1/2015)... ... September 01, 2015 , ... CanAm ... investor-families have received permanent green cards (I-829 petition approval) from the USCIS through ... is the final step of the EB-5 visa process for immigrant investors to ...
(Date:9/1/2015)... Aventura, Florida (PRWEB) , ... September 01, 2015 ... ... across language barriers and international borders seldom arise at the most convenient time ... which is always ready to help. , Universal Translation Services has ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... established the MAP Recovery Network, the Premier Outcomes-Driven Provider Network. It is ... alliance is dedicated to the provision of quality addiction treatment and the ...
(Date:9/1/2015)... ... ... Elizabeth Callahan, MD, founder and medical director of SkinSmart Dermatology® , ... filler treatment for volume loss in the hands. RADIESSE provides an immediate volumizing effect ... delivering smooth, natural-looking results that can last up to one year in most patients. ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... has recently sponsored an educational workshop for physician assistants (PAs) practicing in orthopedics. ... Traumeel™ and Zeel™” was held by Dr. Erick Salado, an orthopedic surgeon at ...
Breaking Medicine News(10 mins):Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 3Health News:MAP Health Management Launches the MAP Recovery Network 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3
... -- Among people with coronary stents, depression was linked to ... study period, researchers found. A coronary stent is a ... keep it open. Coronary arteries supply blood to the heart. ... with an average age 62, who underwent assessment for depression ...
... identify which skills and competencies are considered most critical ... to effectively manage opioid risk in patients treated for ... pain management, and addiction, Experts in this study identified ... in chronic pain patients as how to monitor opioids ...
... March 16 (HealthDay News) -- One man,s example hints at ... diseases before the patient actually gets sick. Researchers analyzed ... Snyder, and then used it to determine his risks for ... fragments of DNA -- and found that he was at ...
... EHEC crisis in Germany in 2011 proved that food brought ... life-threatening diseases. Nevertheless, there have been extremely few investigations ... EU along with food. The gap is now to ... almost three million Euro to cover the costs. Samples ...
... FRIDAY, March 16 (HealthDay News) -- Being unable to ... deadly outcome for older people, new research reveals. ... 52 and older, who completed a test of functional ... to understand health-related information. Specifically, the test assessed a ...
... 2012: Poor dental hygiene behaviours in patients with congenital ... with congenital heart disease floss, brush and visit the ... behaviours when it comes to alcohol, cigarettes and illicit ... congenital heart disease) also have poorer dental hygiene practices ...
Cached Medicine News:Health News:Depression Tied to Earlier Death in Heart Patients 2Health News:Study determines critical skills for PCPs to safely manage opioid risk in chronic pain patients 2Health News:Researcher Uses Genomics to Predict His Odds for Disease 2Health News:Dangerous stowaways: An EU project to look at the international spread of germs on food 2Health News:Poor Reading Skills Might Be Fatal for Older Folks 2Health News:Poor dental hygiene puts congenital heart disease patients at risk of further heart damage 2Health News:Poor dental hygiene puts congenital heart disease patients at risk of further heart damage 3Health News:Poor dental hygiene puts congenital heart disease patients at risk of further heart damage 4
Inquire...
Inquire...
... optical performance, the SZX7 is designed for ... every task, from routine preparations to advanced ... best zoom ratios in its class as ... and accurate reproduction of the original specimen ...
A compact stereomicroscope that is immediately ready for operation and extremely easy to use. Focused on the essential performance features, the Stemi DV4 design concept provides optimum utility....
Medicine Products: